MARKET

CRMD

CRMD

Cormedix
NASDAQ
7.93
+0.43
+5.73%
After Hours: 8.00 +0.07 +0.83% 17:07 05/14 EDT
OPEN
8.55
PREV CLOSE
7.50
HIGH
8.94
LOW
7.86
VOLUME
4.32M
TURNOVER
--
52 WEEK HIGH
17.43
52 WEEK LOW
6.13
MARKET CAP
622.05M
P/E (TTM)
3.906
1D
5D
1M
3M
1Y
5Y
1D
CorMedix (CRMD) Q1 2026 Earnings Transcript
NASDAQ · 3h ago
CorMedix Shares Climb With Higher 1Q Profit, Sales
Dow Jones · 3h ago
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)
TipRanks · 3h ago
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
Benzinga · 3h ago
Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects
TipRanks · 5h ago
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition
Seeking Alpha · 5h ago
3 Low P/E Stocks with Over 40% Upside
TipRanks · 6h ago
Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est
Benzinga · 8h ago
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.